(Q37693934)

22 August 2017

1 reference

title

Levodopa in Parkinson's disease: from the past to the future (English)

1 reference

22 August 2017

1 reference

1 reference

1

Gianni Pezzoli

1 reference

22 August 2017

Michela Zini

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

Expert Opinion on Pharmacotherapy

22 August 2017

published in

1 reference

22 August 2017

volume

11

1 reference

22 August 2017

issue

4

1 reference

22 August 2017

page(s)

627-635

1 reference

Epidemiology of Parkinson's disease

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Neuropsychiatric non-motor aspects of Parkinson’s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Staging of brain pathology related to sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson'

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Levodopa strengths and weaknesses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Survival of Parkinson's disease patients in a large prospective cohort of male health professionals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Levodopa motor complications in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Parkinson's disease. First of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

3-0-Methyldopa uptake and inhibition of L-dopa at the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Evolution and cell biology of dopamine receptors in vertebrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

The neurobiology of dopamine signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

The response to levodopa in Parkinson's disease: imposing pharmacological law and order

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Changes of dopamine turnover in the progression of Parkinson's disease as measured by positron emission tomography: their relation to disease-compensatory mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Levodopa-induced changes in synaptic dopamine in patients with Parkinson's disease as measured by [11C]raclopride displacement and PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Autonomic failure as the initial presentation of Parkinson disease and dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Parkinson's disease and sleepiness: an integral part of PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Continuous dopamine-receptor stimulation in advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Adenosine, adenosine A 2A antagonists, and Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Levodopa and the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

New levodopa sustained-release floating minitablets coated with insoluble acrylic polymer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Skin lipid synthesis inhibition: a possible means for enhancing percutaneous delivery of levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Transport of drugs from the nasal cavity to the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

A pulmonary formulation of L-dopa enhances its effectiveness in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Neural transplantation for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Transplantation of embryonic dopamine neurons for severe Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Can we achieve neuroprotection with currently available anti-parkinsonian interventions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Stereotaxic implantation of autologous adrenal medulla into caudate nucleus in four patients with parkinsonism. One-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Cells therapy for Parkinson's disease--so close and so far away

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

Active Transport of L-Dopa in the Intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656561003598919

10.1517/14656561003598919

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference